

Programm

Ort: Hauptgebäude der Ludwig-Maximilians-Universität München
Geschwister-Scholl-Platz 1, 80539 München

8:30 – 11:45

Educational Symposium Sleep, Depression and Antidepressants

**unterstützt vom European College of Neuropsychopharmacology
[ECNP]**

Vorsitz: D. Nutt [London] / A. Steiger [München]

U. Hemmeter [St. Gallen]

- **Pathophysiology of sleep-EEG changes**

E. Holsboer-Trachsler [Basel]

- **Sleep deprivation as a research tool for antidepressant treatment**

P. Meerlo [Groningen]

- **Disrupted and restricted sleep**

D. Nutt [London]

- **Treatment of insomnia related depression**

L. Staner [Rouffach]

- **Pharmacological management of insomnia related to depression**

M. Hatzinger [Basel]

- **Sleep EEG as predictor of therapy response**

08.30 – 10:00

Freie Vorträge

Schizophrenie

Vorsitz: N. Bergemann [Daun] / R. Wolf [Bochum]

R. Musil [München]

- **Validation of a new scale to assess Quality of Life in schizophrenic patients treated with antipsychotics: the RSM-scale**

J. Genius [München]

- **Alterations in the Ca²⁺ homeostasis in lymphocytes from schizophrenic patients**

M. Obermeier [München]

- **How to handle the PANSS in statistical analyses**

R. Wolf [Bochum]

- **Effects of clozapine (CLZ) on reduced prepulse inhibition (PPI) after neonatal excitotoxic lesion of the ventral thalamus in pubertal and adult rats**

N. Petrovsky [Bonn]

- **Nicotine effects on endophenotypes of schizophrenia**

08:30 – 10:00

Symposium XV

Aktueller Forschungsstand des prädiktiven pharmakologischen Wertes der Lautstärkeabhängigkeit für psychische Störungen

Vorsitz: C. Norra [Bochum] / G. Juckel [Bochum]

T. Hensch [Leipzig]

- **Drugresponse-Prädiktion und Differentialdiagnostik bei psychiatrischen Störungen mittels Lautstärkeabhängigkeit**

G. Juckel [Bochum]

- **Tierexperimentelle und genetische Befunde zur Lautstärkeabhängigkeit**

C. Norra [Bochum]

- **Monoaminerge Challenge-Untersuchungen und Lautstärkeabhängigkeit: Ein Update.**

10.15 – 11.45

Freie Vorträge

Verschiedenes

Vorsitz: U. Schmitt [Mainz] / G.P. Eckert [Frankfurt]

K. Henes [München]

- **Traces of a trauma – Long-lasting changes in brain activity in an animal model of PTSD**

A.G. Schmitt [Würzburg]

- **Stress and Methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD**

U. Schmitt [Mainz]

- **Forced swim-test-related antidepressant effects depend on P-glycoprotein expression in the blood-brain-barrier**

A. Sartorius [Mannheim]

- **Psychomodulation by bilateral deep brain stimulation of the lateral habenula in a patient with long-lasting, therapy-refractory major depression**

G.P. Eckert [Frankfurt]

- **Regulation of the brain isoprenoids farnesyl- and geranylgeranyl-pyrophosphate is altered in male Alzheimer patients**

10:15 – 11:45

Symposium XVI

Molekulare Systembiologie und Neuropsychiatrie

Vorsitz: F. Tretter [München] / P. Gebicke-Haerter [Mannheim]

F. Tretter [München]

- **Perspektiven der Systembiologie für die Neuropsychiatrie**

P. Gebicke-Haerter [Mannheim]

- **System or no-system – that is the question**

W. Mewes [München]

- **10.000 Publikationen pro Jahr – kann die Systembiologie zum Verständnis der Daten beitragen?**

M. Friedrich [St. Augustin]

- **Analyse von Daten zur Signaltransduktion**

11:45 – 13:15

Poster-Sitzung II

Dementia

1. *Association of CSF total tau and phospho-tau (181) with cerebral atrophy in mild cognitive impairment and Alzheimer's disease*
Thomann PA, Kaiser E, Schönknecht P, Pantel J, Essig M, Schröder J
Heidelberg, Frankfurt
2. *2CSF-concentrations of tau-protein, phospho-tau-protein(181) and amyloid-beta(1-42) in patients with stable and non-stable MCI*
Kaiser E, Thomann PA, Seidl U, Schröder J
Heidelberg
3. *Concentrations of functionally important amino acids in cerebrospinal fluid of patients with Alzheimer's disease compared to mild cognitive impairment*
Kaiser E, Schönknecht P, Kassner S, Hildebrandt W, Kinscherf R, Schröder J
Heidelberg, Leipzig, Mannheim
4. *Galantamine improves non-cognitive symptoms as compared to nootropics in outpatients with mild to moderate Alzheimer's disease*
Ibach B, Kühn F, Gerwe M, Diekamp B
Neuss, Oranienburg
5. *Diabetes as a risk factor for mild cognitive impairment in a population based sample in Germany*
Toro P, Schönknecht P, Sattler C, Schröder J
Heidelberg
6. *Ginkgo biloba extract restores amyloid-beta induced mitochondrial deficits*
Rhein V, Baysang G, Rao S, Meier F, Tripodi T, Giese M, Hamburger M, Müller-Spahn F, Eckert A
Basel, Switzerland
7. *Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease*
Arlt S, Schulze F, Eichenlaub M, Maas R, Lehmbeck JT, Schwedhelm E, Boger RH, Wiedemann K, Jahn H
Hamburg
8. *Cognitive leisure activity as a protective factor in a prospective ageing study in Germany*
Toro P, Sattler C, Schröder J
Heidelberg

9. *Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease*
Arlt S, Brassen S, Wilke F, Eichenlaub M, Apostolova I, Buchert R, Jahn H
Hamburg
10. *The influence of galantamine on heart rate variability (HRV)*
Eichenlaub MW, Arlt J, Steigert J, Arlt S, Yassouridis A, Jahn H
Hamburg, Munich
11. *Descriptive analysis of the aripiprazole arm in the risperidone arm in the risperidone long-acting injectable vs quetiapine relapse prevention trial (CONSTATRE)*
de Arce R, Eding E, Marques T, Milanova V, Rancans E, Ibach B, Schreiner A
Madrid, Spain, Tallin, Estonia, Porto, Portugal, Sofia, Bulgaria, Riga, Latvia,
Neuss
12. *EEG-based vigilance and cerebral glucose metabolism – a parallel EEG and FDG PET study*
Günther T, Hesse S, Kendziorra K, Barthel H, Sander C, Olbrich S,
Adamaszek M, Becker G, Sabri O, Hegerl U, Schönknecht P
Leipzig
13. *Cerebrospinal fluid concentrations of functionally important amino acids in patients with Alzheimer's disease compared to mild cognitive impairment*
*Kaiser E, Schönknecht P, Kassner S, Hildebrandt W, Kinscherf R, Schröder J
Heidelberg, Mannheim
14. *Mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease*
Leuner K, Pantel J, Schulz K, Schütt, Lipka U, Eckert A, Müller WE
Frankfurt, Basel, Switzerland

Addiction

15. *No association of alcohol dependence with SLC6A5 and SLC6A9 glycine transporter polymorphisms*
Koller, Zill, , Pogarell, , Bondy, Soyka
Munich, Meiringen, Switzerland
16. *“A chemical love story”: Treatment of a gamma-butyrolacton (GBL)-dependent chemistry student with diazepam - a case report*
Demiralay C, Zorawski M, Wiedemann K, Jahn H
Hamburg
17. *Comparative proteomic analysis with human post mortem brain tissues of drug addicts versus controls: possible impact of beta-tubulin on drug abusing behaviour*
Zill P, Vielsmeier V, Büttner A, Eisenmenger W, Bondy B, Möller H-J
Munich
18. *Low dopamine D2/3 receptor availability is associated with high sensitivity to pain in detoxified alcoholics and healthy controls*
Spreckelmeyer KN, Paulzen M, Weymanns A, VanWaesberghe J, Zalewski J, Vernaleken I, Raptis M, Schaefer KM, Treede RD, Baltus T, Rösch F, Gründer G
Aachen, Mainz
19. *CDT and homocysteine as predictors for alcohol withdrawal seizures*
Hintzen A, Cramer J, Karaguelle D, Frieling H, Bleich S, Hillemacher T
Erlangen, Hannover
20. *Therapeutic drug monitoring of naltrexone in alcohol dependent patients*
*Brünen S, Hiemke C, Finger S, Korf F, Jahn H, Wiedemann K, Kiefer F
Mainz, Hamburg, Mannheim
21. *Disulfiram in the treatment of pathological gambling?*
*Mutschler J, Grosshans M, Bühler M, Diehl A, Kiefer F
Mannheim
22. *Stress-induced alcohol drinking and withdrawal in mice lacking functional natriuretic peptide-A receptors*
Mutschler J, Bilbao A, Goltz von der C, Demiralay C, Jahn H, Wiedemann K, Spanagel R, Kiefer F
Mannheim, Hamburg
23. *Low D2/D3-receptor availability in detoxified alcoholics compared to healthy subjects – PET study with [18F]fallypride*
Paulzen M, Spreckelmeyer KN, Van Waesberghe J, Zalewski M, Baltus T, Raptis M, Rösch F, Vernaleken I, Schäfer WM, Gründer G
Aachen, Mainz

Sleep

24. *Intracortical EEG-vigilance stages and the autonomous nervous system*
Olbrich S, Sander C, Trenner M, Schönknecht P, Hegerl U
Leipzig
25. *Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1)*
Baier PC, Weinhold S, Huth V, Gottwald B, Ferstl R, Hinze-Selch D
Kiel
26. *Disturbed eating behaviour in patients with narcolepsy*
Beitinger PA, Fulda S, Wehrle R, Himmerich H, Wetter TC
Munich, Zurich, Switzerland, Leipzig
27. *A double dissociation of memory impairments in major depression*
*Dresler M, Genzel L, Kluge M, Schüssler P, Steiger A
Munich
28. *Human molecular circadian rhythms and ageing*
Pagani L, Moriggi E, Revell VR, Hack LM, Izakovic J, Lockley SW, Arendt J, Wirz-Justice A, Cajochen C, Skene DJ, Brown SA, Eckert A
Basel, Switzerland, Zurich, Switzerland, Surrey, UK
29. *Effects of intravenous corticotropin-releasing hormone upon sleep EEG in young healthy women*
Schüssler P, Kluge M, Dresler M, Yassouridis A, Steiger A
Munich
30. *Evidence of favorable sleep EEG patterns in adolescent male vigorous football players compared to controls*
Brand S, Djurdjevic A, Beck Johannes, Gerber M, Hatzinger M, Holsboer-Trachsler E
Basel, Switzerland
31. *Long-term treatment of patients suffering from Restless Legs syndrome does not improve satisfaction with life and sleep compared to healthy controls*
Brand S, Hatzinger M, Beck J, Holsboer-Trachsler E
Basel, Switzerland
32. *Adolescent regular exercisers are "better human beings!"*
Brand S, Gerber M, Beck J, Hatzinger M, Holsboer-Trachsler E
Basel, Switzerland
33. *New statistical ways for analyzing sleep data in clinical and preclinical studies*
Möller T, Steiger A, Fahrmeir L, Yassouridis A
Munich
34. *Influence of exogenous ANP on the nocturnal HPA axis and sleep in healthy men*
Demiralay C, Wiedemann K, Kellner M, Yassouridis A, Jahn H
Munich

Pharmacopsychiatry

35. *100 years ago - Psychopharmacotherapy in Emil Kraepelin's Psychiatric Textbook of 1909*
Weber MM, Burgmair W
Munich
36. *D2-receptor occupancies and corresponding plasma concentrations: a comparison of paliperidone extended-release (ER) with risperidone immediate-release (IR)*
*Rossenu S, Mannaert E, Hargarter L, Mehnert A, Vermeulen A
Beerse, Belgium, Neuss
37. *Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers*
Winder-Rhodes SE, Chamberlain SR, Idris MI, Robbins TW, Sahakian BJ, Müller U
Cambridge, UK
38. *Plasma level-dependent effects of methylphenidate and modafinil on processing speed and short term memory capacity parameters of the theory of visual attention (TVA) task*
Finke K, Dodds CM, Bublak P, Regenthal R, Baumann F, Manly T, Müller U
Munich, Cambridge, UK, Leipzig
39. *Sulpiride modulates striatal BOLD signal during the manipulation of information in working memory*
Dodds CM, Clark L, Dove A, Regenthal R, Baumann F, Bullmore ET, Robbins TW, Müller U
Cambridge, UK, Leipzig
40. *Intoxication after extreme oral overdose of quetiapine (36g) to attempt suicide: pharmacological concerns of side effects*
Müller C, Reuter H, Dohmen H
Cologne
41. *Effects of methylphenidate on EEG-vigilance in patients with tumor-associated fatigue syndrome*
Olbrich S, Jahn I, Claus S, Trenner M, Sander C, Schönknecht u, Hegerl U
Leipzig
42. *Vigilance regulation as predictor for response to psychostimulants in ADHD*
*Sander C, Olbrich S, Arns M, Hegerl U
Leipzig, Nijmegen, The Netherlands
43. *In what way dose-related and therapeutic reference ranges are different and what is the use of them?*
Hader A, Haen E
Regensburg

44. *Impact of lipid raft integrity on 5-HT₃ receptor function and its modulation by antidepressants*

*Nothdurfter C, Tanasic S, Di Benedetto B, Rammes G, Kirmeier T, Ganai V, Wagner E, Rein T, Rupprecht R
Munich

45. *Lasting effects of chronic social stress in mice: Impact of antidepressant treatment*

Scharf SH, Sterlemann V, Liebl C, Ganea K, Weber P, Pütz B, Deussing JM, Rein T, Müller MB, Schmidt MV
Munich

Molecular Psychiatry

46. *Genome wide association study on cognitive performance*
Konte B, Giegling I, Hartmann AM, Konnerth H, Muglia P, Ruppert A,
Möller HJ, Rujescu D
Munich
47. *In vivo dopamine D2 receptor binding and personality traits in healthy volunteers: An 18F-fallypride PET study*
Klomp M, Rademacher L, Raptis M, Spreckelmeyer KN, Vernaleken I,
Rösch F, Schäfer WM, Gründer G
Aachen, Mainz
48. *Deletion of FKBP5 alters stress-related parameters in mice*
Schmidt U, Touma C, Gassen N, Christian L, Asmus S, Cox MB, Hausch F,
Schmidt MV, Holsboer F, Rein T
Munich, El Paso, USA
49. *The 5-HTTLPR Polymorphism modulates the association of Serious Life Events (SLE) and impulsivity in patients with borderline personality disorder*
Wagner S, Baskaya Ö, Lieb K, Dahmen N, Tadic A
Mainz
50. *CCK-4 effects upon facial expression in healthy subjects*
Hinkelmann K, Yassouridis A, Mass R, Tenge H, Kellner M, Jahn H,
Wiedemann K, Wolf K
Hamburg, Munich, Marienheide
51. *Association of neuregulin 1 rs3924999 with oculomotor endophenotypes for schizophrenia in healthy volunteers*
Schmechtig A, Vassos E, Kumari V, Hutton SB, Collier DA, Morris RG,
Williams SCR, Ettinger U
London, UK, Sussex, Brighton, UK, Munich
52. *The Brain-Derived Neurotrophic Factor (BDNF) Val66Met polymorphism modulates the effects of serious life events on impulsive aggression in patients with borderline personality disorder*
Wagner S, Baskaya Ö, Lieb K, Dahmen N, Tadic A
Mainz
53. *The catechol O-methyltransferase (COMT) Val158Met polymorphism modulates the association of Serious Life Events (SLE) and impulsive aggression in female patients with borderline personality disorder*
Wagner S, Baskaya Ö, Anicker NJ, Dahmen N, Lieb K, Tadic A
Mainz, Hamburg

54. *Pathological gambling associated with dopamine agonists: predisposing neurobiology investigated with fMRI*
Abler B, Hahlbrock R, Unrath A, Groen G, Kassubek J
Ulm

55. *The role of cytochrome P450 genetic disposition and patient reaction to therapy in a cohort controlled study in private practice - Preliminary results from the MORE Study*
Griffith L, Müller C
Cologne

56. *When desire collides with reason: functional interactions between anteroventral prefrontal cortex and nucleus accumbens underlie the human ability to resist impulsive desires*
Gruber O, Diekhof EK
Göttingen

57. *Polymorphisms of the dopamine beta-hydroxylase (DBH) gene show associations with cognitive flexibility in mentally healthy adults*
*Heck A, Szesny N, Holsboer F, Reppermund S, Ising M
Munich, Sydney, Australia

Miscellaneous

58. *EEG-vigilance in patients with tumor-associated fatigue syndrome in comparison to healthy controls*
Olbrich S, Eplinius F, Sander C, Trenner M, Claus S, Schönknecht P, Hegerl U
Leipzig
59. *EEG-based assessment of wakefulness regulation in patients with mental disorders*
Trenner M, Olbrich O, Sander C, Wilk K, Schönknecht P, Hegerl U
Leipzig
60. *Interaction of BDNF and Connexin43 - two downstream targets of CRH-activated gene transcription*
Hanstein R, Trotter J, Behl C, Clement AB
Mainz
61. *Steroid receptor folding and signaling is regulated by the Hsp70 cochaperones BAG-1M and HspBP1*
Knapp RT, Konzany C, Weidinger E, Hafner K, Holsboer F, Hausch F, Rein T
Munich
62. *Stress-induced gene expression in the paraventricular nucleus of hypothalamus in the mouse strains DBA/2J and C57BL/6J – potential signalling pathways involved*
Tsolakidou A, Czibere L, Pütz B, Trümbach D, Panhuysen M, Deussing JM, Wurst W, Sillaber I, Landgraf R, Holsboer F, Rein T
Munich, Neuherberg
63. *The involvement of FKBP5 in the behavioural and neuroendocrine effects of acute and chronic stress*
Hartmann J, Wagner K, Liebl C, Wolf M, Scharf S, Wang X, Harbich D, Mayer B, Rein T, Schmidt U, Hausch F, Smith D, Cox M, Müller MB, Schmidt MV
Munich, Scottsdale, USA
64. *Consequences of P-gp deficiency for the phenotype of FVB/N (mdr1a/1b -/-) mice and resulting alterations in HPA-System activity*
*Schönfelder Y, Hiemke C, Schmitt U
Mainz
65. *Functional analysis of a novel, stress-inducible transcript in the mouse brain*
Liebl C, Schmidt MV, Schülke JP, Avrabos C, Trümbach D, Eder M, Rein T, Müller MB
Munich

66. *Effects of acute and long-term chronic social stress and aging on cognition: involvement of novel synaptic cell adhesion molecules*
Wolf M, Wang XD, Scharf SH, Liebl C, Holsboer F, Müller MB, Schmidt MV
Munich
67. *The role of pituitary glucocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation following chronic social stress*
*Wagner K, Liebl C, Hartmann J, Harbich D, Mayer B, Wolf M, Scharf S, Wang XD, Schütz G, Müller MB, Schmidt MV
Munich, Heidelberg
68. *Gender differences in social reward anticipation*
Rademacher L, Spreckelmeyer K N, Krach S, Paulus F, Gründer G
Aachen, Marburg
69. *Immunoglobulin G from patients with chronic inflammatory demyelinating polyneuropathy (CIDP) affects presynaptic transmitter release and calcium influx*
Bertram S, Zhang W, Toyka KV, Hatt H, Eder M, Buchwald B
Munich, Bochum, Würzburg
70. *Semicarbazide modulates cortical excitation in mouse brain slices*
Holfelder C, Eder M, Becker K, Zieglgänsberger W, Buchwald B
Munich
71. *Perception and importance of Hafez's poetry of love in modern Iran and Switzerland*
Bajoghli Hafez, Holsboer-Trachsler Edith, Brand Serge
Tehran, Iran, Basel, Switzerland
72. *Ghrelin levels increase after visual perception of food*
Schüssler P, Kluge M, Yassouridis A, Dresler M, Uhr M, Steiger A
Munich

* ausgewählt für "Data-Blitz"

13:15 – 14:15

Satelliten-Symposium II

Bedeutung von Adherence und Motivation als Voraussetzung einer effektiven Langzeitbehandlung schizophrener Patienten

Vorsitz: K. Wolf [Marienheide]

D. Bönsch [Rickling]

- **Verbesserung der Adherence durch langwirksame Neuroleptika und neuropharmakologische Bedeutung**

K. Wolf [Marienheide]

- **Bedeutung von Motivation und emotionale Rollenerfüllung bei der Langzeittherapie schizophrener Patienten**

organisiert von der Janssen-Cilag GmbH, Neuss

14:30 – 16:00

Data-Blitz

Moderation: E. Holsboer-Trachsler [Basel] / B. Schlösser [Reichertshausen]

P. Zimmermann [München]

- **The interplay of variations in the FKBP5 gene and adverse life events in predicting the first onset of depression during a ten-year follow-up**

C. Sander [Leipzig]

- **Vigilance regulation as predictor for response to psychostimulants in ADHD**

A. Heck [München]

- **Polymorphisms of the dopamine beta-hydroxylase (DBH) gene show associations with cognitive flexibility in mentally healthy adults**

S. Jakob [Würzburg]

- **The psychopathology of prenatal stress: The role of epigenetic regulation of brain-derived neurotrophic factor (BDNF) promoter**

M. Dresler [München]

- **A double dissociation of memory impairments in major depression**

R. Ricken [Berlin]

- **Is Algorithm Guided Treatment of Depression Cost-Effective?**

S. Rossenu [Beerse]

- **D2-receptor occupancies and corresponding plasma concentrations: a comparison of paliperidone extended-release (ER) with risperidone immediate-release (IR)**

B. Pfuhlmann [Würzburg]

- **The influence of inflammatory reactions on the serum concentration of clozapine**

D. Holthöwer [Mainz]

- **Influence of P-glycoprotein (P-gp) induction on the pharmacokinetics of risperidone and paliperidone in mouse brain**

A. Menke [München]

- **Genome-wide association study of antidepressant induced treatment emergent suicidal ideation (TESI)**

E. Kaiser [Heidelberg]

- **Cerebrospinal fluid concentrations of functionally important amino acids in patients with Alzheimer's disease compared to mild cognitive impairment**

J. Mutschler [Mannheim]

- **Disulfiram in the treatment of pathological gambling?**

K. Wagner [München]

- **The role of pituitary glucocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation following chronic social stress**

S. Brünen [Mainz]

- **Therapeutic drug monitoring of naltrexone in alcohol dependent patients**

C. Nothdurfter [München]

- **Impact of lipid raft integrity on 5-HT₃ receptor function and its modulation by antidepressants**

Y. Schönfelder [Mainz]

- **Consequences of P-gp deficiency for the phenotype of FVB/N (mdr1a/1b -/-) mice and resulting alterations in HPA-System activity**

16:30 – 18:15

Symposium XVII

The Endocannabinoid System as a Potential Target for the Treatment of Neuropsychiatric Disorders

Vorsitz: F. M. Leweke [Mannheim] / P. Roser [Bochum]

B. Lutz [Mainz]

- **The endocannabinoid system in recovering from internal and external stress**

P. Roser [Bochum]

- **Cannabinoids and cognitive functioning**

K. Müller-Vahl [Hannover]

- **Cannabinoids in the treatment of movement disorders**

D. Koethe [Köln]

- **Evidence for cannabinoid treatments of affective disorders?**

F. M. Leweke [Mannheim]

- **A translational approach targeting the endocannabinoid system in schizophrenia**

16:30 – 18:15

Symposium XVIII

Neue Wirkprinzipien und Strategien zur Therapieoptimierung der Major Depression

Vorsitz: A. Tadić [Mainz] / H. Stadler [München-Martinsried]

K. Lieb [Mainz]

- **Was gibt es Neues in der Behandlung der Depression? Eine kritische Auseinandersetzung mit neuen Analysen zur Wirksamkeit und Verträglichkeit von Antidepressiva**

H. Stadler [München-Martinsried]

- **Neue Targets und Wirkprinzipien: COX-2-Antagonisten und P2X7-Agonisten**

M. Adli [Berlin]

- **Algorithmusgestützte Entscheidungen in der antidepressiven Therapie – welche Patienten brauchen Stufenpläne?**

A. Tadić [Mainz]

- **Rationale und Design des „Randomised clinical trial comparing early medication change [EMC] strategy with treatment as usual [TAU] in patients with Major Depressive Disorder – the EMC trial**

Freier Vortrag

C. Otte [Hamburg]

- **Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study**

16:30 – 18:15

Symposium XIX

Astrozyten, Microglia und Immunaktivierung bei Schizophrenie

Vorsitz: N. Müller [München] / A-M. Myint [München]

J. Steiner [Magdeburg]

- **S100B und Mikroglia bei Schizophrenie: Ergebnisse von post mortem Studien**

M. Rothermundt [Münster]

- **Untersuchungen zu S100B im Behandlungsverlauf bei Schizophrenie**

M. Schwarz [München]

- **Kynurenin-Stoffwechsel und Immunsystem – neue Befunde bei Schizophrenie**

N. Müller [München]

- **COX-2 Inhibition als Therapieansatz bei Schizophrenie**

Freier Vortrag

L. Schöneck [Magdeburg]

- **Dysregulated expression of the oligodendroglial transcriptionfactor Olig 2 in schizophrenia and depression**

16:30 – 18:15

Symposium XX

Pharmakologische Targets in der Suchttherapie

Vorsitz: F. Kiefer [Mannheim] / G. Winterer [Düsseldorf]

G. Winterer [Düsseldorf]

- **Nikotin: Molekulare Mechanismen und pharmakologische Targets**

V. Auwärter [Freiburg]

- **Spice und weitere Kräutermischungen: Harmloses Räucherwerk oder Designer-Cannabinoide?**

R. Spanagel [Mannheim]

- **Präklinische Befunde zur Pharmakotherapie bei Kokainabhängigkeit**

Freie Vorträge

U. Ettinger [München]

- **Effects of Acute Nicotine on Brain function in Healthy Smokers and Non-smokers: Estimation of Inter-individual Response Heterogeneity**

P. Netter [Gießen]

- **Are food and nicotine craving mediated by the same transmitter related drugs and respective hormone responses?**

T. Passie [Hannover]

- **A new classification of the psychoactive substances (stimulants, entaktogens, hallucinogens)**

16:30 – 18:15

Symposium XXI

Wirkstoffkonzentrationsbestimmungen – wie man das Beste daraus macht

Vorsitz: A. Conca [Bozen] / C. Hiemke [Mainz]

N. Bergemann [Daun]

- **TDM während Schwangerschaft und Stillzeit**

A. Seeringer [Ulm]

- **TDM und pharmakogenetische Tests in der Pharmakovigilanz – wann und was?**

A. Hader [Regensburg]

- **Dosis-bezogene und therapeutische Referenzbereiche: Was ist der Unterschied?**

A. Köstlbacher [Regensburg]

- **Rechner-gestützte Befundkommentierung bei TDM von Psychopharmaka**

Freier Vortrag

U. Bonnet [Essen]

- **Modulatory effects of various neuropsychopharmaca on intracellular pH of hippocampal CA3-neurons in vitro (guinea pig)**